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Abstract Although ADHD signiﬁcantly affects the
quality of life (QoL) of patients and their families, QoL in
children with ADHD has rarely been investigated in
association with psychopathological proﬁle, and the rela-
tionship remains unclear. The open-label OBSEER study
evaluated the effectiveness and tolerability of Equasym
XL
, a modiﬁed-release methylphenidate, in routine care
of children and adolescents (aged 6–17 years) with ADHD.
At baseline, questionnaires assessing psychopathological
proﬁle (Strengths and Difﬁculties Questionnaire, SDQ;
parental ratings) and QoL (KINDL; parent, child or ado-
lescent versions) were completed; QoL was reassessed at
ﬁnal visit. We analysed the relationship between psycho-
pathology and parent/patient-rated QoL in ADHD at
baseline. Data from 721 consecutively referred children
and adolescents were analysed. QoL was similarly low
from parent and self-ratings and independent of severity on
the SDQ subscale hyperactivity/inattention. Self-ratings
indicated that additional conduct disorder was associated
with further reduction in QoL. Similarly, children with
high scores from parent and adolescent ratings on the SDQ
subscale conduct problems had reduced QoL on some
KINDL subscales. Adolescents with ADHD not receiving
medication at baseline reported lower QoL than those
already on medication. Results show that children and
adolescents with ADHD have low QoL, independent of
core symptom severity. Additional conduct problems may
further impact QoL negatively, while ADHD medication
use may show a trend towards improved QoL. Not all
psychopathological problems associated with ADHD affect
QoL similarly. As parents appear to have a less critical
view of QoL compared with children’s self-ratings, both
parent and child ratings should be included in clinical
assessments.
Keywords SDQ  Quality of life  KINDL questionnaire 
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Introduction
Over the past few years, clinical work and research on
quality of life (QoL) has become increasingly important in
improving both physical and mental health in children. In
the ﬁeld of attention deﬁcit hyperactivity disorder
(ADHD), several studies on QoL have been published and
were included in a systematic review [7]. This level of
interest is not surprising due to the complexity of the
relationships; QoL is not only inﬂuenced by the disorder
itself, but also by many proximal (i.e. family, friendship)
and distal (socioeconomic and cultural) factors. In addition
to its core symptoms of attention deﬁcit, hyperactivity and
impulsivity, ADHD is associated with numerous develop-
mental, cognitive, emotional, social and academic impair-
ments [12, 17, 25]. One possible reason for this might be
that in ADHD, more than 80% of children and adults are
likely to have at least one other psychiatric disorder and
more than 50% are likely to have two [10, 23]. Thus, in
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exception [24]. These comorbidities, as well as the other
proximal and distal factors, affect the QoL of both patients
and their families [7].
There is signiﬁcant potential for overlap between the
instruments designed to measure QoL and those used to
measure psychopathology or functional impairment. Clear
distinctions between symptoms (e.g. low mood or poor
concentration) and their potential effects (i.e. functional
impairment and/or reduced QoL), and also between func-
tional impairment on the one hand and QoL on the other,
are desirable [7]. Otherwise, there is a clear risk that
apparent QoL effects are so closely related to symptoms
and functional impairment that their association with the
disorder will become a tautology [7]. In this context, it
becomes evident that examining not only the relationship
between QoL and categorical psychopathology (i.e. an
ADHD diagnosis), but also the relationship with dimen-
sional psychopathology (i.e. functional impairment and
symptom scores), would result in improved understanding
of the complex interplay of one or more disorders as well
as of proximal and distal factors.
For an outcome as subjective as QoL, the inﬂuence of
the rater’s role should also be highlighted. A parent’s rating
of their child’s QoL gives only one perspective of the
overall impact of the illness on QoL. This may limit the
validity of studies that do not ask children for their view on
their own QoL. Such a difference is reﬂected, for example,
by the only modest levels of agreement between the child’s
and other informants’ ratings of QoL [13, 15], particularly
with regard to non-observable aspects (such as emotional
or social functioning). Parent ratings may, however, pro-
vide an important alternative perspective. Therefore, in
studies on ADHD, measures of QoL as well as measures of
psychopathology should include both a child- and a parent-
rated version.
The aim of this analysis was to have a detailed look at
the relationships between dimensional psychopathology
and both parent- and child-rated QoL in ADHD. This
analysis also evaluated the validity of the QoL concept, as
described by Coghill et al. [5]. By studying correlative
considerations, the relationship between QoL and psycho-
pathological problems may be better understood. The
effects of medication on QoL in ADHD are reported in a
companion paper [8].
Methods
Study design
The open-label, prospective, multicentre, observational,
post-marketing OBSEER (OBservation of Safety and
Effectiveness of Equasym XL
 in Routine care) study was
designed primarily to assess the effectiveness and safety of
Equasym XL
1 (Shire Pharmaceuticals Ireland Limited,
Ireland) in children and adolescents with ADHD and is
described in full elsewhere [8]. Here, pre-speciﬁed out-
comes of QoL and the dimensional psychopathological
proﬁle (SDQ) are examined and related to each other cross-
sectionally at the baseline visit in post hoc analyses.
Patients and treatment
Patients with ADHD (diagnosed according to the Diag-
nostic and Statistical Manual of Mental Disorders, Fourth
Edition, Text Revision [DSM]-IV-TR [1] or the Interna-
tional Classiﬁcation of Diseases [ICD]-10 criteria [26])
aged 6–17 years and attending school were included if
treatment with Equasym XL
 was planned by the treating
physician. Patients either could have received prior medi-
cation or were medication naive. The study was conducted
in accordance with local regulations and under the thera-
peutic responsibility of the attending physicians; ethics or
institutional review board approval was not required for this
study. Written informed consent was obtained from parents.
Assessments
QoL
QoL was assessed using the Kinder Lebensqualita ¨tsfragebo-
gen (KINDL) questionnaire for the assessment of health-
related QoL in childhood and adolescence [18]. This is a
validated tool comprising 24 items, with six subscores
(physical well-being, emotional well-being, self-esteem,
family, friends and school). Three versions were used
according to age group: KID-KINDL was used for children
aged 6–11 years; the self-reported KIDDO-KINDL for ado-
lescentsaged12–17 years;andKINDLforparentsofpatients
aged6–17 years.Scoresweretransformedsothattherangeof
possiblevaluesfor the subscores and the total score was from
0 (most negative state) to 100 (most positive state).
SDQ
Parents were asked to complete a version of the Strengths
and Difﬁculties Questionnaire (SDQ) that supplements the
25 core items on speciﬁc strengths and difﬁculties with an
1 Equasym XL is the UK trade name, and is registered and marketed
by Shire in the following countries under the following trademarks:
Denmark, Equasym Depot; Finland, Equasym Retard; France,
Quasym LP; Germany, Equasym Retard; Ireland, Equasym XL;
Netherlands, Equasym XL; Norway, Equasym Depot; Sweden,
Equasym Depot; South Korea, Metadate CD; Mexico, Metadate
CD. Information correct at August 2011.
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123overall rating of whether their child has emotional or
behavioural problems [11, 22]. Each of the 25 items is
rated as being not true (0), somewhat true (1) or certainly
true (2); each of the ﬁve subscales consists of ﬁve items,
thus yielding scores between 0 and 10 for each subscale.
Although the wording chosen for 10 of the 25 SDQ ques-
tions addresses positive behavioural attributes, ﬁve of these
10 item scores were inverted before being summed up.
Thus, four of the SDQ subscales represent problem scores
(emotional symptoms, conduct problems, hyperactivity/
inattention and peer problems), which were added together
to obtain a total difﬁculties score ranging from 0 to 40. The
ﬁfth subscale assesses the positive aspect of prosocial
behaviour. Scores for each subscale were considered to be
normal, borderline or abnormal. Total difﬁculties scores
were considered to be normal (range 0–12), borderline
(range 13–15) or abnormal (range 16–40).
Statistical analyses
The following outcomes were assessed: parent-rated
dimensional psychopathological severity according to the
SDQ and parent- and self-rated QoL at baseline.
Results presented are for the intent-to-treat population.
Analysis of variance (ANOVA) modelling was performed
to determine the effects of parent-rated SDQ subscale
scores and total difﬁculties score on QoL. In subgroup
analyses, patients were assigned to groups according to
their diagnosis (ADHD only versus ADHD with conduct
disorder) and treatment prior to starting Equasym XL
 (no
treatment; or treatment with modiﬁed-release methylphe-
nidate [MPH], immediate-release MPH [MPH-IR] admin-
istered once daily, MPH-IR administered several times
per day or ‘other’, for which treatment was unspeciﬁed
[atomoxetine, amphetamine or insufﬁciently speciﬁed]).
Finally, correlation coefﬁcients between the parent-repor-
ted SDQ subscales and total difﬁculties score and the
parent- and self-rated QoL scales in the study (KINDL,
KID-KINDL and KIDDO-KINDL) were calculated.
Scale means for parent ratings of both the SDQ and the
KINDL scales were compared with those from the BELLA
study, which assessed the prevalence of general and spe-
ciﬁc mental health problems in a representative sample of
children and adolescents in Germany [19, 21].
Results
Study population
In total, 852 patients were enrolled in the study. Thirty
patients were excluded from the analysis due to invalid
data; a further 101 patients were excluded because their
SDQ data were missing or incomplete. Therefore, 721
patients were included in the analysis population. Baseline
demographics are described elsewhere [8].
Relationship between SDQ scores in the normal range
and QoL
Self-ratings of QoL from children aged 6–11 years showed
that those with normal (range 0–5) scores on the hyperac-
tivity/inattention subscale of the SDQ tended to achieve
higher, albeit not signiﬁcantly, scores on the KID-KINDL
friends subscale than if they had borderline (6) or abnormal
(range 7–10) SDQ scores (mean [SD] 68.4 [19.8] vs. 61.3
[20.7] and 65.5 [22.7]; F (2, 474) = 2.445; 0.05\P B 0.1).
Children with normal (range 0–12) or borderline (range
13–15) SDQ total difﬁculties scores had higher scores,
indicating better QoL, on the KINDL friends subscale than
children with abnormal (range 16–40) SDQ scores (mean
[SD] 63.2 [19.4] and 63.4 [20.8] vs. 58.7 [21.2]; F (2,
718) = 3.817; P B 0.05). Compared with children with
borderline or abnormal SDQ total difﬁculties scores, those
with normal scores tended to rate themselves as more
content on the KID-KINDL school subscale (mean [SD]
61.8 [21.3] vs. 53.6 [23.0] and 58.2 [22.5]; F (2, 474) =
2.589; 0.05\P B 0.1).
Adolescents with normal SDQ total difﬁculties scores
tended to show the highest QoL on the KIDDO-KINDL
family subscale compared with those with borderline or
abnormal scores (mean [SD] 73.5 [20.9] vs. 59.3 [23.6] and
66.6 [22.9]; F (2, 164) = 2.545; 0.05\P B 0.1).
Correlation between severity of SDQ scores and QoL
Correlation analyses showed that children with high SDQ
total difﬁculties scores had signiﬁcantly lower QoL on the
parent-rated KINDL total score (r =- 0.091; P B 0.05)
and on the subscales emotional well-being (r =- 0.106;
P B 0.01) and friends (r =- 0.131; P B 0.01; Table 1).
There was also a similar trend for the subscale self-esteem
(r =- 0.063; 0.05\P B 0.1).
ChildrenwithhighscoresontheSDQemotionalproblems
subscale had signiﬁcantly lower values on the parent-rated
KINDL total score (r = –0.097; P B 0.01) and on the sub-
scales emotional well-being (r =- 0.096; P B 0.05) and
friends (r =- 0.118; P B 0.01). A similar trend was found
for the subscale school (r =- 0.073; 0.05\P B 0.1).
For the SDQ subscale conduct problems, children with
higher scores tended to have lower QoL based on the
parent-rated KINDL scale emotional well-being (r =
-0.069; 0.05\P B 0.1), although this was not signiﬁcant.
There were no signiﬁcant correlations between the SDQ
subscale hyperactivity/inattention and any of the parent-
rated KINDL subscales.
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123Children scoring high on the SDQ subscale peer prob-
lems had signiﬁcantly lower QoL on the KINDL subscales
emotional well-being (r =- 0.084; P B 0.05) and friends
(r =- 0.134; P B 0.01). A similar trend was observed for
the KINDL total score (r =- 0.067; 0.05\P B 0.1).
There were no signiﬁcant correlations between psycho-
pathology and QoL self-ratings from children aged
6–11 years (KID-KINDL; data not shown).
Adolescents who had high SDQ total difﬁculties scores
had a signiﬁcantly lower QoL on the KIDDO-KINDL sub-
scales self-esteem (r =- 0.170; P B 0.05) and friends
(r =- 0.190; P B 0.05), with a trend for lower QoL on the
family subscale (r =- 0.128; 0.05\P B 0.1; Table 2).
Children with high scores on the SDQ subscale emotional
problems tended to have lower scores on the KIDDO-
KINDLsubscalesself-esteem(r =- 0.143;0.05\P B 0.1)
and friends (r =- 0.137; 0.05\P B 0.1).
Adolescents with high scores on the SDQ subscale
hyperactivity showed a signiﬁcantly lower QoL on the
KIDDO-KINDL total score (r =- 0.174; P B 0.05),
family (r =- 0.155; P B 0.05) and friends (r =- 0.202;
P B 0.01; Table 2). Furthermore, a similar trend was found
for the KINDL subscale school (r =- 0.132; 0.05\
P B 0.1). Adolescents with high scores on the SDQ sub-
scale peer problems tended to have a lower QoL on
the KIDDO-KINDL subscale self-esteem (r =- 0.153;
P B 0.05). There were no signiﬁcant correlations between
the SDQ subscales conduct problems or prosocial behav-
iour and any of the KIDDO-KINDL subscales.
Compared with the recent normative reference values
for children and adolescents in Germany obtained in the
epidemiological BELLA study [19, 21], children and
adolescents with ADHD, as seen in the OBSEER study,
were signiﬁcantly more severely affected on every SDQ
subscale and had a signiﬁcantly lower QoL on every
KINDL subscale (Table 3).
Comorbid conduct disorder and QoL
One-way ANOVA was used to test whether there were
differences between scores on each scale associated with
having an additional conduct disorder (Table 4). Of note,
SDQ scores, including those for the subscale conduct
problems, did not differ between diagnostic groups.
Table 1 Correlation between
the SDQ (parent ratings) and
KINDL total scores and
subscales (parent ratings)
(N = 721)
Italics indicate signiﬁcant or
borderline signiﬁcant results
* P B 0.05; ** P B 0.01;
T 0.05\P B 0.1; ns = not
signiﬁcant (two-tailed test,
Spearman’s rank correlation)
SDQ
KINDL Total
difﬁculties
score
Subscales
Emotional
problems
Conduct
problems
Hyperactivity/
inattention
Peer
problems
Prosocial
behaviour
Total score -0.091* -0.097** -0.055 ns -0.019 ns -0.067
T 0.017 ns
Subscales
Physical well-being -0.003 ns -0.038 ns 0.005 ns 0.031 ns 0.00 ns -0.008 ns
Emotional well-being -0.106** -0.096* -0.069
T -0.032 ns -0.084* 0.063
T
Self-esteem -0.063
T -0.057 ns -0.050 ns -0.003 ns -0.055 ns 0.013 ns
Family -0.032 ns -0.025 ns -0.055 ns 0.009 ns -0.012 ns 0.040 ns
Friends -0.131** -0.118** -0.039 ns -0.053 ns -0.134** 0.003 ns
School -0.043 ns -0.073
T -0.024 ns -0.026 ns 0.009 ns -0.038 ns
Table 2 Correlation between
the SDQ (parent ratings) and the
KIDDO-KINDL total scores
and subscales (patient ratings,
age 12–17 years) (N = 167)
Italics indicate signiﬁcant or
borderline signiﬁcant results
* P B 0.05; ** P B 0.01;
T 0.05\P B 0.1; ns = not
signiﬁcant (two-tailed test,
Spearman’s rank correlation)
SDQ
KIDDO-KINDL Total
difﬁculties
score
Subscales
Emotional
problems
Conduct
problems
Hyperactivity/
inattention
Peer
problems
Prosocial
behaviour
Total score -0.159* -0.089 ns -0.042 ns -0.174* -0.119 ns -0.025 ns
Subscales
Physical well-being -0.056 ns -0.091 ns 0.014 ns -0.021 ns -0.047 ns -0.104 ns
Emotional well-being -0.076 ns -0.030 ns 0.004 ns -0.109 ns -0.069 ns -0.079 ns
Self-esteem -0.170* -0.143
T -0.054 ns -0.098 ns -0.153* -0.014 ns
Family -0.128
T -0.024 ns -0.120 ns -0.155* -0.045 ns 0.100 ns
Friends -0.190* -0.137
T 0.021 ns -0.202** -0.143 ns -0.120 ns
School -0.032 ns 0.023 ns 0.050 ns -0.132
T -0.029 ns 0.033 ns
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123Similarly, there were no differences in QoL between
children with or without additional conduct disorder from
KINDL parent ratings.
In contrast, self-ratings from children aged 6–11 years
(KID-KINDL) showed that those with an additional conduct
disorder had lower QoL than those without (Table 4). This
applied to the total score (F (1, 427) = 6.246; P B 0.05) and
the subscales self-esteem (F (1, 432) = 6.264; P B 0.05),
family (F (1, 430) = 11.683; P B 0.001) and friends
(F(1, 431) = 4.230; P B 0.05). A similar trend was found for
the subscale school (F (1, 430) = 3.015; 0.05\P B 0.1),
although this was not signiﬁcant.
Adolescents aged 12–17 years (KIDDO-KINDL)
showed a similar pattern to children for the QoL evalua-
tion. The most impaired were the adolescents with an
additional conduct disorder, with an effect on the total
score (F (1, 135) = 11.715; P B 0.001) and the scales
physical well-being (F (1, 137) = 5.011; P B 0.05),
emotional well-being (F (1, 137) = 6.366; P B 0.05),
self-esteem (F (1, 137) = 4.639; P B 0.05), family
(F (1, 136) = 10.291; P B 0.01) and friends (F (1, 137) =
4.660; P B 0.05).
Medication subgroups and QoL
When subgroups of patients were compared according to
whether they had received prior medication or not, no sta-
tistically signiﬁcant differences were found either for the
KINDL or for the KID-KINDL (Table 5). For the KIDDO-
KINDL, adolescents receiving any prior medication scored
signiﬁcantly higher on the KIDDO-KINDL subscale school
(F (1, 166) = 2.448; P B 0.05) than those who had not
received prior medication. A similar trend was found for the
subscales self-esteem (F (1, 166) = 2.376; 0.05\P B 0.1)
and family (F (1, 166) = 1.997; 0.05\P B 0.1). There
were no signiﬁcant differences in SDQ scores according to
whether or not the patient had received prior medication.
Discussion
ADHD is associated with a variety of behavioural
problems; therefore, knowledge of the complete psycho-
pathological proﬁle is important for treatment decisions
and follow-up. Danckaerts et al. [7] showed that a robust
negative effect on QoL was reported by the parents of
children with ADHD across a broad range of psychopa-
thology symptoms. Additional comorbid disorders, such
as oppositional deﬁant disorder [16], and increased
symptom levels also seem to predict reduced QoL [14].
For this reason, it is useful to know what inﬂuence
psychopathological proﬁle has on QoL. We investigated
the relationship between these two parameters in this
analysis of the observational OBSEER trial. An advan-
tage of this study is that self-assessment of children was
included and thus ﬁndings are not limited to just the
views of parents or caregivers, unlike the majority of
QoL studies [7].
Table 3 Comparison of scale
means and effect sizes for
parent-rated SDQ and KINDL
scores at baseline in the
OBSEER study with a reference
population from the BELLA
study
The Cohen’s d effect size was
calculated as small
(0.20 C d\0.50), medium
(0.50 C d\0.80) or large
(0.80 C d)[ 6]
SD standard deviation
*** P B 0.001
Parent SDQ ratings Study Cohen’s d t-test
BELLA [21]; n = 2,406
Mean (SD)
OBSEER; n = 721
Mean (SD)
t Signiﬁcance
Total difﬁculties 7.8 (5.2) 18.6 (4.3) -2.3 45.59 ***
Emotional symptoms 1.8 (1.8) 3.8 (2.5) -0.9 23.20 ***
Conduct problems 1.9 (1.5) 4.2 (1.7) -1.4 31.30 ***
Hyperactivity/
inattention
3.0 (2.2) 6.9 (1.6) -2.0 23.41 ***
Peer problems 1.4 (1.6) 3.7 (1.4) -1.5 50.10 ***
Prosocial behaviour 7.9 (1.7) 6.7 (2.1) 0.6 15.54 ***
Parent KINDL ratings Study Cohen’s dt -test
BELLA [19]; n = 2,863
Mean (SD)
OBSEER; n = 721
Mean (SD)
t Signiﬁcance
Total score 76.3 (10.1) 62.9 (13.3) 1.1 30.51 ***
Physical well-being 76.5 (17.3) 71.4 (18.3) 0.3 6.52 ***
Emotional well-being 80.8 (12.8) 67.6 (17.6) 0.9 22.51 ***
Self-esteem 68.8 (14.2) 55.1 (18.5) 0.8 21.84 ***
Family 77.7 (14.3) 62.2 (19.4) 0.9 24.95 ***
Friends 78.0 (13.4) 60.2 (20.9) 1.0 24.31 ***
School 76.0 (16.0) 60.9 (18.7) 0.9 20.10 ***
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123Our results show that classifying scores on the SDQ
subscale hyperactivity/inattention and the SDQ total
problem score as normal, borderline or abnormal did not
sufﬁciently differentiate between children’s QoL as rated
by their parents. This may be due to the fact that, in this
fairly homogeneous clinical sample, most children with
ADHD had low QoL. Indeed, this was reﬂected in both
parent and self-ratings. Thus, it is probable that an apparent
‘bottom effect’ did not allow QoL to be adequately dif-
ferentiated using severity-categorized SDQ values in this
sample.
Although ADHD symptom severity appeared to have
little inﬂuence on QoL, having a comorbid conduct disor-
der had a substantial impact. However, this was evident
only on self-ratings; ratings from parents did not differ
between QoL of children with ADHD only and those with
ADHD plus a conduct disorder. The ﬁndings indicate that
adolescents, in particular, experience a signiﬁcant decrease
in QoL if they have a comorbid conduct disorder. Thera-
pists should consider this aspect when planning multimodal
treatment and adjust the sequence of interventions
according to the subjective view of impairment given by
the patient.
Parent and child ratings did not identify any signiﬁcant
differences in QoL due to prior medication. However,
adolescents not taking medication at baseline had signiﬁ-
cantly lower QoL on the KIDDO-KINDL subscale school
compared with adolescents taking any MPH medication. A
Table 4 Diagnosis and QoL/
behavioural problems
ANOVA analysis of variance,
F90.0 disturbance of activity
and attention, F90.1
hyperkinetic conduct disorder,
QoL quality of life, SD standard
deviation
* P B 0.05; ** P B 0.01;
*** P B 0.001;
T 0.05\P B 0.1; ns = not
signiﬁcant
Rating scale N Diagnosis ANOVA
F 90.0; n = 370 F 90.1; n = 268 F Signiﬁcance
Mean (SD) Mean (SD)
QoL
Parent KINDL ratings
Total score 638 63.1 (13.3) 62.6 (13.4) 0.269 ns
Physical well-being 638 72.1 (17.7) 70.5 (19.2) 1.157 ns
Emotional well-being 638 67.6 (17.9) 67.2 (17.0) 0.102 ns
Self-esteem 638 55.6 (18.4) 54.8 (18.6) 0.229 ns
Family 638 63.4 (18.7) 60.8 (20.5) 2.677 ns
Friends 638 59.5 (21.4) 61.1 (20.6) 0.915 ns
School 684 60.7 (18.8) 61.0 (18.7) 0.054 ns
Patient KID-KINDL ratings (age 6–11 years)
Total score 429 66.6 (12.6) 63.2 (15.0) 6.246 *
Physical well-being 429 72.2 (17.0) 73.4 (17.9) 0.754 ns
Emotional well-being 429 71.4 (16.5) 70.6 (17.8) 0.159 ns
Self-esteem 429 59.7 (19.2) 54.2 (22.6) 6.264 *
Family 429 70.1 (18.6) 63.5 (22.7) 11.683 ***
Friends 429 66.6 (20.6) 62.1 (23.7) 4.230 *
School 429 59.6 (21.8) 55.7 (23.5) 3.015
T
Patient KIDDO-KINDL ratings (age 12–17 years)
Total score 137 69.7 (10.7) 62.4 (14.1) 11.715 ***
Physical well-being 137 76.3 (15.6) 70.5 (16.3) 5.011 *
Emotional well-being 137 76.8 (15.5) 69.3 (16.8) 6.366 *
Self-esteem 137 62.0 (17.9) 55.9 (22.6) 4.639 *
Family 137 71.7 (20.2) 58.8 (26.1) 10.291 **
Friends 137 72.5 (17.2) 65.6 (22.4) 4.660 *
School 137 58.7 (16.9) 54.2 (16.4) 2.046 ns
Behavioural problems
Parent SDQ ratings
Total difﬁculties 638 18.3 (6.3) 18.9 (6.3) 0.857 ns
Emotional symptoms 638 3.8 (2.3) 3.8 (2.6) 0.365 ns
Conduct problems 638 4.0 (2.2) 4.3 (2.3) 1.044 ns
Hyperactivity/inattention 638 7.0 (2.2) 7.0 (2.2) 0.183 ns
Peer problems 638 3.6 (2.5) 3.8 (2.4) 1.163 ns
Prosocial behaviour 638 6.8 (2.0) 6.6 (2.1) 2.501 ns
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123similar trend was found for the subscales self-esteem and
family, but the majority of scales showed no differences.
Hence, the positive effect of medication on QoL seen in
some previous trials [4, 9] was observed only as an overall
trend in this study.
Scores for the SDQ subscales and total difﬁculties had
varying associations with the QoL assessment scales used
in the OBSEER study. For parental ratings, the highest
correlation (negative) was seen between the SDQ subscale
peer problems and the KINDL subscale friends. Thus,
children with lower QoL according to the subscale friends
had signiﬁcantly more problems with their peers. It is
likely that these scales measure similar, but opposing,
aspects of behaviour. Furthermore, it was found that a high
psychopathological value on the SDQ subscales peer
problems, emotional problems and total problems is
accompanied by lower QoL on the KINDL subscales
emotional well-being, friends and total score. However,
Table 5 Medication subgroups and QoL/behavioural problems
Rating scale N Prior treatment ANOVA
None
n = 187
Mean (SD)
MPH-IR
once-daily
n = 82
Mean (SD)
MPH-IR
repeated
n = 239
Mean (SD)
MPH-MR
n = 179
Mean (SD)
Other/no
speciﬁcation
n = 34
Mean (SD)
F Signiﬁcance
QoL
Parent KINDL ratings
Total score 721 63.4 (13.3) 61.0 (12.9) 62.8 (13.9) 63.4 (12.5) 63.3 (12.0) 0.577 ns
Physical well-being 721 71.7 (18.5) 70.1 (18.6) 72.3 (18.3) 70.4 (18.8) 75.0 (13.9) 0.723 ns
Emotional well-being 721 68.7 (15.9) 65.0 (17.8) 66.2 (18.9) 69.7 (17.5) 67.5 (15.2) 1.584 ns
Self-esteem 721 54.9 (19.1) 53.2 (20.7) 55.6 (18.5) 55.6 (16.8) 54.4 (18.4) 0.303 ns
Family 721 63.0 (19.0) 58.8 (19.8) 62.8 (20.1) 62.4 (18.8) 61.8 (19.7) 0.784 ns
Friends 721 61.3 (21.3) 59.8 (20.0) 59.3 (20.8) 61.4 (21.2) 55.7 (20.8) 0.770 ns
School 721 61.5 (19.5) 58.9 (17.7) 60.5 (19.4) 61.0 (17.7) 65.6 (17.2) 0.852 ns
Patient KID-KINDL ratings (age 6–11 years)
Total score 477 63.8 (13.3) 65.8 (14.3) 67.2 (14.1) 65.4 (12.6) 62.9 (16.1) 1.349 ns
Physical well-being 477 74.4 (18.3) 70.4 (15.3) 71.9 (18.0) 72.8 (16.9) 74.0 (14.3) 0.682 ns
Emotional well-being 477 70.3 (16.7) 69.3 (17.3) 73.2 (17.8) 70.7 (16.5) 69.1 (17.7) 0.951 ns
Self-esteem 477 73.7 (21.4) 61.5 (19.4) 59.6 (21.5) 56.6 (18.7) 58.0 (23.3) 2.171
T
Family 477 66.0 (19.5) 69.8 (20.8) 70.1 (20.4) 67.4 (20.1) 59.0 (23.9) 1.806 ns
Friends 477 64.4 (20.2) 64.6 (21.6) 67.0 (23.2) 66.5 (20.6) 60.8 (25.9) 0.576 ns
School 477 53.9 (23.1) 59.2 (23.4) 61.3 (21.7) 58.1 (20.2) 56.6 (29.0) 2.109
T
Patient KIDDO-KINDL ratings (age 12–17 years)
Total score 167 63.3 (14.3) 66.0 (10.3) 69.0 (11.3) 67.3 (14.0) 66.2 (7.9) 1.250 ns
Physical well-being 167 71.7 (18.1) 76.2 (17.1) 75.1 (18.0) 73.0 (14.4) 73.3 (17.5) 0.340 ns
Emotional well-being 167 75.6 (18.1) 68.8 (11.4) 73.9 (15.4) 73.8 (17.5) 71.6 (10.2) 0.571 ns
Self-esteem 167 51.7 (20.5) 60.6 (15.4) 61.5 (16.3) 62.6 (19.4) 61.9 (21.0) 2.376
T
Family 167 61.6 (27.3) 63.5 (18.7) 72.9 (21.9) 68.1 (21.5) 58.5 (13.2) 1.997
T
Friends 167 69.1 (20.7) 66.5 (15.6) 70.7 (18.5) 68.8 (20.8) 70.5 (16.3) 0.165 ns
School 167 50.1 (17.7) 60.2 (15.3) 59.7 (16.6) 57.6 (17.5) 61.4 (14.2) 2.448 *
Behavioural problems
Parent SDQ ratings
Total difﬁculties 721 19.0 (6.5) 17.4 (5.4) 18.6 (6.7) 18.7 (6.0) 18.2 (5.6) 0.993 ns
Emotional symptoms 721 3.9 (2.4) 3.6 (2.4) 3.9 (2.6) 3.7 (2.4) 3.5 (2.6) 0.498 ns
Conduct problems 721 4.4 (2.4) 3.7 (2.2) 4.1 (2.4) 4.2 (2.1) 4.4 (1.8) 1.494 ns
Hyperactivity/inattention 721 7.0 (2.2) 6.8 (1.9) 6.7 (2.1) 7.3 (2.3) 6.9 (2.4) 1.778 ns
Peer problems 721 3.8 (2.5) 3.3 (2.2) 3.9 (2.6) 3.5 (2.3) 3.4 (2.4) 1.270 ns
Prosocial behaviour 721 6.6 (2.0) 6.6 (2.0) 6.6 (2.1) 6.8 (2.1) 7.1 (1.9) 0.777 ns
ANOVA analysis of variance, IR immediate release, MPH methylphenidate, MR modiﬁed release, QoL quality of life, SD standard deviation
* P B 0.05;
T 0.05\P B 0.1; ns = not signiﬁcant
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123these signiﬁcant relationships are based on low correlation
coefﬁcients and thus need to be interpreted with caution. In
addition, adolescents with high scores on the SDQ scale
hyperactivity had a signiﬁcantly lower QoL (KIDDO-
KINDL). This association was most notable for the total
score and the subscales family and friends.
The results of this study are consistent with the results of
another observational trial, the ADORE study [2], which
recruited a comparable sample (with regard to sample size
and demographic characteristics) of children with ADHD
across Europe. In that study, baseline SDQ values were
similar to those in the current study, and the QoL of chil-
dren with ADHD in the ADORE study was markedly lower
at baseline [20] than the norms for children in the com-
munity [3].
However, according to SDQ scales, a relatively high
proportion of children and adolescents in the OBSEER
study were classiﬁed as having impaired psychopathology.
A total of 67.1% of children were classiﬁed as ‘abnormal’
on the SDQ total score and 57.1% on the SDQ subscale
hyperactivity/inattention, compared with 6–9% of children
in the normative BELLA study [21].
A limitation of our analysis is that the clinical diagnoses
were not based on structured interviews, which may limit
the reliability of the ﬁndings. Furthermore, for the
ANOVA, the multiple testing of correlations was not
adjusted and therefore should be regarded as exploratory.
Finally, the prior medication status of patients was not
identiﬁed at randomization, which makes it difﬁcult to
interpret the presence or absence of meaningful
differences.
In addition to providing further evidence that QoL is low
in children with ADHD, our results show that different
psychopathological problems inﬂuence QoL in different
ways. According to child and adolescent self-ratings,
having a comorbid conduct disorder was associated with
signiﬁcantly lower QoL. Based on our results, it is rec-
ommended that when assessing QoL, children’s ratings
should be used in conjunction with parental ratings for a
complete picture.
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